DRMAW
Dermata Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
−50.00%Price chart
Jul 10Jul 17Jul 24Jul 29Aug 3Aug 6Aug 12Aug 17
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.5x
Market Cap
$615.87
MomentumView details →
1D Return
−50.00%
YTD Return
−97.51%
RSI (14)
31.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.5x
Market Cap
$615.87
RSI (14)
31.3
MomentumView details →
1D Return
−50.00%
YTD Return
−97.51%
Similar companies
Latest newsMore news →
Dermata Therapeutics announced the commercial launch of its Tome Foundational Treatment skincare product, now available for purchase on its website.10d agoDermata Therapeutics, Inc. signed a private placement agreement on August 18, 2026, to raise approximately $3.4 million in gross proceeds through the sale of common stock, pre-funded warrants, Series E warrants, and Series F warrants.19d agoDermata Therapeutics announced the launch date of its first commercial product, Tome Foundational Treatment, expected on August 25, 2026.24d ago